Sio Gene Therapies Inc. (NASDAQ:SIOX) Expected to Announce Earnings of -$0.24 Per Share

Analysts expect Sio Gene Therapies Inc. (NASDAQ:SIOXGet Rating) to post earnings per share (EPS) of ($0.24) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Sio Gene Therapies’ earnings. Sio Gene Therapies reported earnings per share of ($0.19) during the same quarter last year, which would indicate a negative year-over-year growth rate of 26.3%. The company is expected to issue its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Sio Gene Therapies will report full year earnings of ($1.04) per share for the current financial year. For the next financial year, analysts expect that the business will post earnings of ($1.18) per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Sio Gene Therapies.

Several research analysts recently weighed in on SIOX shares. HC Wainwright cut Sio Gene Therapies from a “buy” rating to a “sell” rating in a research note on Thursday, April 28th. SVB Leerink lowered shares of Sio Gene Therapies from an “outperform” rating to a “market perform” rating and cut their target price for the company from $6.00 to $1.00 in a research note on Tuesday, February 1st. Cantor Fitzgerald lowered shares of Sio Gene Therapies from an “overweight” rating to a “neutral” rating and set a $0.80 price target on the stock. in a research report on Thursday, April 28th. Finally, Zacks Investment Research upgraded Sio Gene Therapies from a “sell” rating to a “hold” rating in a research report on Thursday, April 14th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $4.43.

Hedge funds have recently added to or reduced their stakes in the company. Prosight Management LP lifted its position in shares of Sio Gene Therapies by 92.6% in the 3rd quarter. Prosight Management LP now owns 493,208 shares of the company’s stock valued at $1,070,000 after acquiring an additional 237,093 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Sio Gene Therapies in the 3rd quarter valued at approximately $103,000. State Street Corp lifted its position in shares of Sio Gene Therapies by 42.9% in the 4th quarter. State Street Corp now owns 157,200 shares of the company’s stock valued at $203,000 after acquiring an additional 47,200 shares in the last quarter. Morgan Stanley lifted its position in shares of Sio Gene Therapies by 136.5% in the 3rd quarter. Morgan Stanley now owns 68,383 shares of the company’s stock valued at $149,000 after acquiring an additional 39,471 shares in the last quarter. Finally, Clearline Capital LP lifted its position in shares of Sio Gene Therapies by 79.7% in the 1st quarter. Clearline Capital LP now owns 392,691 shares of the company’s stock valued at $263,000 after acquiring an additional 174,185 shares in the last quarter.

SIOX traded up $0.02 during trading on Friday, reaching $0.31. The stock had a trading volume of 1,249,397 shares, compared to its average volume of 604,563. The firm has a market capitalization of $22.97 million and a price-to-earnings ratio of -0.37. Sio Gene Therapies has a 1-year low of $0.23 and a 1-year high of $2.95. The stock has a 50 day moving average of $0.49 and a two-hundred day moving average of $0.91.

About Sio Gene Therapies (Get Rating)

Sio Gene Therapies, Inc, a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. The company develops AXO-Lenti-PD, in vivo lentiviral gene therapy, which is in Phase II clinical trials for the treatment of Parkinson's disease; AXO-AAV-GM1, an investigational gene therapy , which is in Phase I/II clinical trials for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2, an investigational gene therapy, which is in Phase I/II clinical trials for the treatment of GM2 gangliosidosis.

Featured Stories

Get a free copy of the Zacks research report on Sio Gene Therapies (SIOX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sio Gene Therapies (NASDAQ:SIOX)

Want More Great Investing Ideas?

Receive News & Ratings for Sio Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sio Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.